A new clinical study on Quest Diagnostics (DGX) Haystack MRD test reported high accuracy in detecting residual and recurrent solid tumor cancers, giving investors fresh information about this cancer-focused diagnostics offering.
Quest Diagnostics shares have climbed over the year, with a 90-day share price return of 11.27% and a year to date share price gain of 32.81%. The 3 year total shareholder return of 102.51% suggests momentum has been strong over a longer horizon.
Spot 32 healthcare AI stocks that, like Quest Diagnostics, are aiming to turn advanced diagnostics and data-driven testing into real commercial traction in healthcare.Quest Diagnostics now trades near US$230, with consensus targets clustered closer to US$249 and a wider intrinsic value gap still implied. Does that recent run fully capture the Haystack MRD upside or leave room on the table?
Most Popular Narrative: 7% Undervalued
Quest Diagnostics is priced at $230.81 against a widely followed fair value view of $247.40, so the narrative still points to some upside potential even after the recent share price strength.
The continuing shift toward preventive healthcare and wellness, supported by Quest Diagnostics’ roughly US$300 million consumer business that is growing at about 30% and is expected by management to grow more than 20% annually over the next 3 to 5 years with margins above the corporate average, is setting up a larger recurring revenue base and higher earnings contribution from cash-pay testing.
See why 20 investors see Quest Diagnostics as 7% undervalued.
Result: Fair Value of $247.40 (UNDERVALUED)
Still, policy pressure on Medicare reimbursement and lingering cost inflation could undermine the Quest Diagnostics margin story and challenge the current upside narrative.
Find out about the key risks to this Quest Diagnostics narrative.
Next Steps
Mixed signals in the Quest Diagnostics story today. Consider the new Haystack MRD data, the valuation gap, and sentiment together, then weigh both sides using 4 key rewards and 1 important warning sign.
Looking for more Quest Diagnostics sized opportunities?
Quest Diagnostics may be front of mind today, but your next strong idea could be hiding elsewhere. Do not leave your watchlist half built.
- Target stability first by searching for resilient businesses with strong fundamentals using the 31 resilient stocks with low risk scores.
- Hunt for quality at a compelling price by scanning companies that screen as attractively priced through the 27 high quality undervalued stocks.
- Build a watchlist of potential future leaders by reviewing the 20 high quality undiscovered gems before everyone else starts paying attention.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com